Neutralizing Abs against DNASE1 are also common in SLE (22), and the enzyme is ineffective at degrading chromatin (21), which likely explains why DNASE1 did not benefit patients with SLE in a clinical trial (23). This evidence concerns the gene DNASE1 and systemic lupus erythematosus.